Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Traws Pharma ( (TRAW) ).
On December 12, 2025, Traws Pharma‘s Compensation Committee approved stock options and restricted stock units for its executive officers. This decision, under the 2021 Incentive Compensation Plan, aims to incentivize key leaders, potentially impacting the company’s operational focus and market positioning.
The most recent analyst rating on (TRAW) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.
Spark’s Take on TRAW Stock
According to Spark, TipRanks’ AI Analyst, TRAW is a Underperform.
Traws Pharma’s overall stock score is low due to significant financial challenges and bearish technical indicators. However, recent corporate events, including positive trial data and new financing, provide a glimmer of hope for future improvements, albeit with high risk.
To see Spark’s full report on TRAW stock, click here.
More about Traws Pharma
Average Trading Volume: 325,712
Technical Sentiment Signal: Sell
Current Market Cap: $18.62M
Learn more about TRAW stock on TipRanks’ Stock Analysis page.